Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2012
At a glance
- Drugs Cilengitide (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jul 2012 Results published in Investigational New Drugs.
- 05 Nov 2010 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History